





2







5

	u enjoy our webinars and feel others may benefit, too? us spread the word!
Becoi	me a promoter:
F	Receive special emails to share within your organization! unclen.org/promoter
Follov	v our social channels:
	facebook.com/unclcn o unclinebergercancernetwork
	in linkedin.com/in/unclcn
Send	questions to unclcn@unc.edu or (919) 445-1000
	Thank you for spreading the word!



Our Presenter



Jake Stein, MD, MPH

Jake Stein, MD, MPH is a medical encotogist with a clinical flocus on carring for patients with sacromas. These are are and heterogeneous cancers that can affect patients of all page, including delicements and young adults, let has always strived to listen closely to his patients and address their concerns, while collaborating with colleagues carross describers and bringing he highest quality, most cutting edge medical science to achieve the best possible outcomes for these patients. Egypt is a core value for him and st a public institution like which is a supplication of the patients of the patients of highest quality carror can't but a patients, regardless of their background or concursations. My goal is to always be in partnership with my patients, neighting the complexities of a cancer journey together, side by side.

He adap a health services researches and his work focuses on how to optimize care delivery systems to improve the quality of cancer core for all patients, expecially those who have been tradiscoally undersord. This inches understanding the gips and barriers within our current delivery systems, followed by the development and testing of interventions to improve these agreems. Some of his current projects involve evaluating how to improve the delivery of precision medicine for patients with advanced cancer, developing precidive models to determine what patients are at high risk for complications from cancer therapy and how to reade what this cancer therapy and how to reade but misk, and how to make sarcoma care for young people better aligned with their goals and needs.

8

Our Presenter

011	r P	re	CD	nt	ΔΙ	ľ

5. Jake Stein, MD, MPH, a medical oncologist caring for patients with sarcoma - a group of rare and heterogeneous cancers.

10

Our Presenter

- **5.** Jake Stein, MD, MPH, a medical oncologist caring for patients with sarcoma a group of rare and heterogeneous cancers.
- He has a particular interest in caring for young people with cancer and how to improve their care and outcomes.

11

Our Presenter

- Jake Stein, MD, MPH, a medical oncologist caring for patients with sarcoma - a group of rare and heterogeneous cancers.
- 4. He has a particular interest in caring for young people with cancer and how to improve their care and outcomes.
- He is a cancer care delivery researcher meaning he studies how to improve how we get people the cancer care they need.

Our Presenter

- Jake Stein, MD, MPH, a medical oncologist caring for patients with sarcoma - a group of rare and heterogeneous cancers.
- He has a particular interest in caring for young people with cancer and how to improve their care and outcomes.
- He is a cancer care delivery researcher meaning he studies how to improve how we get people the cancer care they need.
- He is a medical educator he works with residents and fellows and enjoy helping teach folks how to think about complex medical topics.

13


Our Presenter

- Jake Stein, MD, MPH, a medical oncologist caring for patients with sarcoma a group of rare and heterogeneous cancers.
- He has a particular interest in caring for young people with cancer and how to improve their care and outcomes.
- 3. He is a cancer care delivery researcher meaning he studies how to improve how we get people the cancer care they need.
- He is a medical educator he works with residents and fellows and enjoy helping teach folks how to think about complex medical topics.
- 1. He is a proud father of two (4 yo and 1 yo), a musician and a basketball player in his free time.

14

Our Presenter

- **5.** Jake Stein, MD, MPH, a medical oncologist caring for patients with sarcoma a group of rare and heterogeneous cancers.
- He has a particular interest in caring for young people with cancer and how to improve their care and outcomes.
- He is a cancer care delivery researcher meaning he studies how to improve how we get people the cancer care they need.
- He is a medical educator he works with residents and fellows and enjoy helping teach folks how to think about complex medical topics.
- **1.** He is a proud father of two (4 yo and 1 yo), a musician and a basketball player in his free time.




ACCME Disclosure


This activity has been planned and implemented under the sole supervision of the Course Director, Stephanie Wheeler, PhD, MPH, in association with the UNC Office of Continuing Professional Development (CPD). The course director received research support from AstraZeneca (ended June 2023) and Pitzer Medical Foundation (ended December 2023). These financial relationships have been mitigated, CPD staff have no relevant financial relationships with ineligible companies as defined by the ACCME.


A potential conflict of interest occurs when an individual has an opportunity to affect educational content about health-care products or services of a commercial interest with which he/she has a financial relationship. The speakers and planners of this learning activity have not disclosed any relevant financial relationships with any commercial interests pertaining to this activity.

The presenter has no relevant financial relationships with ineligible companies as defined by the ACCME.

17







20

Overview/Objectives

- Identify the most common oncologic emergencies.
- Describe key elements to diagnosis common oncologic emergencies.
- Recognize critical aspects of oncologic emergency management.

UNC

I UNC

Case 1

A 75-year-old man with a recent diagnosis of lung cancer presents to the ER with back pain. He also mentions that he has had several falls in the past week, and his feet feel "clumsy." MRI spine shows a vertebral body mass with extension into the epidural space and compression of the spinal cord with associated cord edema.


What is the most appropriate next step in management?

- A. Biopsy of the epidural mass
- B. Corticosteroids followed by radiation therapy
- C. Platinum based chemotherapy
- D. Radiation therapy alone

UNC

I UNC

22



23

Case 1

A 75-year-old man with a recent diagnosis of lung cancer presents to the ER with back pain. He also mentions that he has had several falls in the past week, and his feet feel "clumsy." MRI spine shows a vertebral body mass with extension into the epidural space and compression of the spinal cord with associated cord edema. What is the most appropriate next step in management?

- A. Biopsy of the epidural mass
- B. Corticosteroids followed by radiation therapy
- C. Platinum based chemotherapy
- D. Radiation therapy alone


SLH	L		٦

I UNC

SPINAL CORD COMPRESSION

- Occurs in up to 5% of all patients with cancer, 20% of those with spinal mets
- Most common: breast, lung, prostate
- Also seen in lymphoma, renal cell, multiple myeloma
- Associated with poor prognosis
- CRITICAL to diagnose and treat ASAP
 - Neurological status at presentation and rapidity of onset predict outcome





25

Etiology

- · Usually due to direct extension from spinal bony mets
- Can occur from destruction of cortical bone causing vertebral body collapse and displacement of bony fragments into the spinal canal
- Most common in thoracic spine (70%) due to smaller available free space within thoracic canal
 - Lumbosacral spine (20%)
 - Cervical spine (10%)

Lawton, et al, 2019, JCO. Assessment and Management of Patients With Metastatic Spinal Cord Compression A Multidisciplinary Review Gould Rothberg BE, et al. Oncologic emergencies and urgencies: A comprehensive review. CA Cancer J Clin.

UNC

I UNC

26

Symptoms of SCC

- Back pain (~90%) -> often first presenting symptom
- **This is why back pain in a cancer patient is a "red flag" and merits prompt imaging**
- Weakness (35-75%)
- · Sensory loss
- Bowel, bladder dysfunction (late finding)
- Gait ataxia

Lawton, et al. 2019, JCO. Assessment and Management of Patients With Metastatic Spinal Cord Compressio. A Multidisciplinary Review Gould Rothberg BE, et al. Oncologic emergencies and urgencies: A comprehensive review. CA Cancer J Clin 2022. https://doi.org/10.3222/eaac.21727





Diagnosis

- · Early recognition is essential
- · MRI is imaging modality of choice
- Recommendation is to image the entire spine as many patients have multiple sites of disease
- Often sensory level affected does not correspond to area of suspected cord compression

Lanten, et al. 2019, JCD, Assessment and Management of Patients With Metastatic Spinal Cord Compression A Multidisciplinary Perietie A. Oncologic emergencies and urgencies: A comprehensive review. CA Cancer J Clin. 2022. https://doi.org/10.3322/casc.21727

UNC

I UNC

28

Treatment

- · Immediate dexamethasone
 - Increases likelihood of ambulation post treatment, improves pain scores
 - Typical dosing: 10mg IV x1 followed by 16mg daily in divided doses (ie, 4mg q6hrs)
- · Opiate analgesics
- Prompt neurosurgery and rad-onc consultation (even in the middle of the night!)
 - Surgery + XRT improved outcomes (ability to ambulate) over XRT alone

UNC

Patchell 2005 Lancet, Vecht, Neurology 1989, Sorenson, Eur J Cancer 1994



29


Case 2


A 54-year-old man presents with facial swelling and cough. Vital signs show normal temperature, BP 160/95, HR 106, RR 20, O2 sat 92% on room air. Exam reveals facial plethora as well as bilateral jugular venous distention. CT scan of the chest demonstrates a LUL mass with compression of the SVC in addition to mediastinal lymphadenopathy.


What is the most appropriate next step in management?

- A. Chemotherapy
- B. Combined chemotherapy and radiation therapy
- C. Corticosteroids
- D. Mediastinoscopy and biopsy
- E. Radiation therapy









Etiology

- · Non-malignant causes
 - Catheter related
 - Pacemaker leads
 - Infectious (TB, syphilis, fibrosing mediastinitis)
- Malignancy-related SVC
 - NSCLC: 50%, portends poor prognosis
 - SCLC: 25%NHL: 10%

UNC Azizi et al. JACC Cardiovasc Interv. 2020



34

Presentation

- Can be subacute or quite rapid, depending on degree of collateralization
- Facial, neck, and upper extremity swelling
- · Dilated chest veins
- Dyspnea, cough, hoarseness
- · Headache, confusion, or lethargy

UNC Azizi et al. JACC Cardiovasc Interv. 2020



35



UNC

I UNC

Diagnosis

- · CT chest with contrast is imaging of choice
- · MR venography is a potential alternative
- Prompt Mediastinoscopy vs CT guided biopsy
- Usually can delay treatment while obtaining tissue diagnosis since treatment guided by tumor type (i.e. R-CHOP vs platinum-based chemotherapy)

2111	١,		

UNC Azizi et al. JACC Cardiovasc Interv. 2020



37

Treatment

- Emergent if stridor/respiratory compromise or lethargy/coma
- Endovascular stent placement or thrombolysis are emergent therapy options (VIR consult)
- · Radiotherapy: benefit in 72 hours
- · Chemotherapy: benefit in 1-2 weeks
- Steroids: Only if laryngeal edema or known steroid responsive cancer
- · Diuretics: Unclear benefit

678	UNC	Azizi et al. JACC Cardiovasc Interv. 2020	



38

Case 3


An 85-year-old woman presents with fatigue, lethargy and constipation. She has advanced breast cancer with bony metastases. She does not have previous medical history aside from her cancer.


Labs are notable for an elevated calcium to 15.1.

What is the most appropriate immediate next step?

- A. Intravenous bisphosphonate
- B. Intravenous furosemide
- C. Intravenous glucocorticoids
- D. Intravenous normal saline

I UNC





41

•Most common cause among inpatients is cancer • Malignancy diagnosed in >33% of all patients who present to ED with hypercalcemia •Affects ~20% of cancer patients • ~50% die within 1 month Valid et al, StafPauris, 2024 Clines, Curr Opin Endocrin, 2011 18:339-346; image gemented by ChatGPT4 limage gemented. 3/4/2024.

Pathophysiology

- Tumor secretion of PTHrP (Humoral hypercalcemia of malignancy) (~80%)
 - PTHrP increases osteoclastic bone resorption and enhances calcium resorption through renal tubules
- Local bone destruction (i.e. bone mets) -> local release of cytokines, osteoclast activating factors (~20%)
- 1,25-dihydroxy vitamin D production (<1%)
- Increases calcium absorption in gut and osteoclast activity
- Ectopic secretion of PTH (<1%)

Vakiti at al. StatDearle 2024 Clinae Curr Onin Endovrin 2011 18:330-346

1 UNC

I UNC

43



44

Symptoms

- · Weakness, fatigue
- Polyuria, polydipsia (nephrogenic DI)
- GI symptoms (abdominal pain, nausea, vomiting, constipation)
- Psychiatric symptoms (memory loss, apathy)
- · Bone pain
- · "Stones, bones, groans, psychiatric overtones"

Vakiti et al, StatPearls, 2024. Clines, Curr Opin Endocrin, 2011 18:339-346;



45

UNC

Diagnosis

- Serum lab value does not necessarily account for acuity or degree of symptoms
 - Mild < 12 mg/dl
 - Moderate 12-14 mg/dl
 - Severe > 14 mg/dl
- · Remember to use ionized or corrected calcium

Vakiti et al, StatPearls, 2024. Clines, Curr Opin Endocrin, 2011 18:339-346;

M UNC

I UNC

46

Treatment

- · Fluids: NS at initial rate of 200-300 cc/h
 - Loop diuretics only if fluid overload, CHF, or renal failure
- · Bisphosphonates
 - Block osteoclastic bone resorption, delayed onset (24-48h)
 - Zoledronic acid 4 mg over 15 min or pamidronate
- Calcitonin (SubQ or IM)
 - Early onset of action: hours, but short duration (48h)
 - Can help temporize while bisphosphonates take effect
- · Consider steroids if increased calcitriol production
- Consider HD for patients w/ neurological symptoms, calcium >18, renal failure, CHF

UNC

Vakiti et al, StatPearls, 2024. Clines, Curr Opin Endocrin, 2011 18:339-346;



47

Case 4

A 26-year-old man presents with 2 weeks of rapidly enlarging cervical lymphadenopathy, abdominal distention and fever.

VS: 39C, BP 90/60, HR 115 and RR 24. He has significant cervical and axillary LAD. Spleen is palpable and a firm abdominal mass. Hgb 10.5, WBC 65k, 35% PMNs and 65% atypical lymphs, Plt 90K Cr 3.8, LDH 12,000, Phos 9.9, K 6.6, Uric acid 18.6


A lymph node biopsy reveals Burkit lymphoma.

Which is the most appropriate immediate next step in treatment?


- A. Combination chemotherapy
- B. Corticosteroid therapy
- C. Hemodialysis, IV normal saline, and rasburicase
- D. Radiation therapy

NC.	3/13/2024
P. C. C. C. C.	





A 26-year-old man presents with 2 weeks of rapidly enlarging cervical lymphadenopathy, abdominal distention and fever. VS: 39C, BP 90/60, HR 115 and RR 24. He has significant cervical and axillary LAD. Spleen is palpable and a firm abdominal mass. Hgb 10.5, WBC 65K, 35% PMMs and 65% atypical lymphs, Plt 90K Cr 3.8, LDH 12,000, Phos 9.9, K 6.6, Uric acid 18.6 A lymph node biopsy reveals Burkitt lymphoma. Which is the most appropriate immediate next step in treatment? A. Combination chemotherapy B. Corticosteroid therapy C. Hemodalysis, IV normal saline, and rasburicase D. Radiation therapy



Laboratory Abnormalities

- Hyperkalemia
 - Life-threatening arrhythmias
- · Hyperuricemia
 - Crystallize in renal tubules -> obstructive uropathy
 - Can lead to acute renal failure
- · Hyperphosphatemia
 - Leads to hypocalcemia, tetany, seizures, arrhythmias

Gould Rothberg BE, et al. CA Cancer J Clin. 2022.

UNC	



52

Risk Factors for TLS

- · *High grade lymphoma
 - Burkitt's lymphoma
- *ALL with WBC ≥ 100,000
- *AML with WBC ≥ 50,000
- · High tumor cell proliferation rate
- Chemosensitivity
- Large tumor burden: Bulky disease, WBC ≥50,000, or pre-tx LDH > 2x ULN
- Dehydration
- Pre-existing CKD

othberg BE, et al. CA Cancer J Clin. 2022






53

Management

- · Prevention: If high or intermediate risk
 - Allopurinol: Decreases uric acid formation
 - IVF
 - Consider rasburicase
- · Treatment: FLUIDS
- · Rasburicase: Degrades uric acid to allantoin
 - Consider if pre-existing hyperuricemia
 - Relative contraindication: G6PD deficiency -> can lead to hemolysis and methemoglobinemia
- Treat electrolyte abnormalities
- HD in severe cases


	V	v

I UNC



Case 5		
A 28-year-old previously healthy woman presents with 3 weeks of progressive fatigue, dyspnea on exertion, and easy bruising. T 37.2C, BP 124/78, HR 106, RR 22, O2 sat 83% on RA, improved to 95% on 4L. Exam reveals petechiae, ecchymoses, pallor. Mild cervical lymphadenopathy. Crackles in bilateral lung bases, no peripheral edema. No hepatosplenomegaly.	o	
Hb 7.4, WBC 108,400 (ANC 400), Plt 18,000 BUN 24, Cr 1.1 Normal PT, PTT, elevated fibrinogen, D-dimer Peripheral blood smear - blasts		
Which of the following is the most appropriate treatment?		
A. Imatinib B. Induction chemotherapy C. Leukapheresis D. Rituximab		
<u>unc</u>	I	UNC

56



Case 5

A 28-year-old previously healthy woman presents with 3 weeks of progressive fatigue, dyspnea on exertion, and easy bruising, T37.2C, BP 12478, HR 106, RR 22. O2 sat 83% on RA, improved to 95% on 4L. Exam reveals petechiae, ecchymoses, pallor. Mild cervical lymphadenopathy. Crackles in bilateral lung bases, no peripheral edema. No hepatospienomegaly.

Hb 7.4, WBC 108,400 (ANC 400), Plt 18,000 BUN 24, Cr 1.1

Normal PT, PTT, elevated fibrinogen, D-dimer Peripheral blood smear - blasts

Which of the following is the most appropriate treatment?

- A. Imatinib
- B. Induction chemotherapy
 C. Leukapheresis




58

M UNC



- Presenting symptoms:
- Pulmonary: dyspnea, hypoxia, infiltrates
- Neurologic: AMS, vision changes, headache, tinnitus
- · Fever in up to 80%
- Spontaneous TLS and

Image courtesy of chatGPT4 image generator: 3/13/2024



59

Hyperleukocytosis/Leukostasis

- Hyperleukocytosis = WBC >100k
- Leukostasis = increased viscosity, white cell plugs in the microvasculature due to blasts being less deformable, endothelial activity
- · Most common with AML
- · Can also see in ALL, CML in blast crisis
- · Rare in CLL and CML in chronic phase

UNC 3/13/2024



Treatment

- · One week mortality of 20-40% if untreated
- · Treatment:
 - Hydroxyurea for cytoreduction (in asymptomatic patients) or induction chemotherapy
 - Leukapheresis if symptomatic -> involves MICU admission, line placement, transfusion med input
 - IV hydration and allopurinol for TLS prophylaxis
 - Avoid PRBC transfusions prior to leukoreduction, if possible

	Schiffer et al.	UptoDate.	2024
TALL S	-		

I UNC

61

Case 6

You receive a phone call at 2:30am on a Thursday night. A 24-year-old man with a recent diagnosis of DLBCL reports that he awoke to some mild chills, and his temperature is 100.7. He recently was discharged from the hospital after his first cycle of R-CHOP. He received G-CSF on the day prior to D/C.

Tonight, he reports that he has felt in his usual state of health. No new cough, shortness of breath, abdominal pain, nausea, diarrhea, headache, dysuria. He lives very far away in rural NC. He is quite worried about flu and COVID and does not want to come to the hospital if it can be avoided.


What is the best course of action?

- A. Send a message to his nurse navigator for an infusion visit tomorrow
- B. As long as he feels fine, he can go back to sleep and not worry about it
- C. Advise him to drive up to UNC for admission
- D. Order a prescription for levofloxacin at his local 24-hour pharmacy and encourage good PO intake, advise hospital admission if he feels any worse
- E. Recommend that he immediately present to his local ER for evaluation



I UN

62



Case 6

You receive a phone call at 2:30am on a Thursday night. A 24-year-old man with a recent diagnosis of DLBCL reports that he awoke to some mild chills, and his temperature is 100.7. He recently was discharged from the hospital after his first cycle of R-CHOP. He received G-CSF on the day prior to D/C.

Tonight, he reports that he has felt in his usual state of health. No new cough, shortness of breath, abdominal pain, nausea, diarrhea, headache, dysuria. He lives very far away in rural NC. He is quite worried about flu and COVID and does not want to come to the hospital if it can be avoided.

What is the best course of action?

- A. Send a message to his nurse navigator for an infusion visit tomorrow
- B. As long as he feels fine, he can go back to sleep and not worry about it
- C. Advise him to drive up to UNC for admission
- D. Order a prescription for levofloxacin at his local 24-hour pharmacy and encourage good PO intake, advise hospital admission if he feels any worse
- E. Recommend that he immediately present to his local ER for



64

NEUTROPENIC FEVER

- Fever: oral temp ≥ 38.4C or
- ≥38.0C, sustained over 1 hour Neutropenia: ANC <500 or expected to decrease
- Critical to evaluate patient and start antibiotics ASAP



Image courtesy of chatGPT4 image generator: 3/13/2024

65

Neutropenia

- · Risk of neutropenic fever depends on depth and duration of neutropenia and comorbidities
- · Generally due to myelosuppressive chemotherapy
 - Solid tumors: duration of neutropenia < 5 days
 - Heme malignancies: can last >14 days
 - BMT: can be months
 - Highest risk usually 5-10 days after chemo
- · Can also occur w/o chemo or at presentation in heme malignancy or if marrow involvement
- New AML is functionally neutropenic
- · Remember to check diff

UNC

Wingard J. UptoDate. 2023



Approach to Patient with Neutropenic Fever

- · Thorough physical exam
 - Skin, oral cavity, line sites
 - Abdomen (typhlitis), perianal area (not DRE)
- - CBC diff, CMP
 - UA and culture
 - Blood cultures (if CVC, at least 1 from line)
 - COVID-19 PCR
 - "Sepsis Bundle"
- CXR
- Further workup guided by sx/exam







Wingard J. UptoDate, 2023

67

Neutropenic Fever Treatment

- · Rapid treatment CRITICAL!
- Anti-pseudomonal coverage (cefepime) for all patients
- Vancomycin
 - Suspected catheter-related infection
 - Skin or soft tissue infection
 - Hemodynamic instability
- · Use zosyn if c/f anaerobes, carbapenem if c/f ESBLs
- · Consider adding antifungal if persistent fever after 4-7 days of broad spectrum coverage without clear source

1 UNC

Wingard J. UptoDate. 2023



68

Thank you!


Never be afraid to speak up or ask for help if you are concerned about a patient. Identifying these emergencies early and reacting quickly can save lives.












71







74



We Thank You for Participating Today!
UNC Lineberger Cancer Network
Ask to sign up for our monthly e-newsletter
Email: unclcn@unc.edu
Call: (919) 445-1000
Check us out at
unclen.org and learn.unclen.org
Look for us on these social media platforms
facebook.com/unclcn o unclinebergercancernetwork
in linkedin.com/in/uncicn